$410.5 M

MSTX Mkt cap, 18-Jun-2018
Mast Therapeutics Net income (Q1, 2018)-26.8 M
Mast Therapeutics EBIT (Q1, 2018)-32.1 M
Mast Therapeutics Cash, 31-Mar-201822.1 M
Mast Therapeutics EV388.7 M

Mast Therapeutics Financials

Mast Therapeutics Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

128 k

Revenue growth, %

(100%)

R&D expense

12.9 m19.4 m28.3 m20.8 m18.5 m

General and administrative expense

9.3 m11.1 m

Operating expense total

12.9 m19.4 m28.3 m30.1 m30 m

Depreciation and amortization

363 k

EBIT

(21.5 m)(29.3 m)(39.4 m)(36.5 m)(30 m)

EBIT margin, %

(28481%)

Interest expense

2.1 m1.2 m

Interest income

60.3 k69 k130 k122 k

Pre tax profit

(21.5 m)(28.7 m)(39.8 m)(38.5 m)(33.4 m)

Income tax expense

2.4 m3.6 m

Net Income

(21.5 m)(28.7 m)(39.8 m)(36.1 m)(29.8 m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Revenue

45 k94 k

R&D expense

3.1 m4.3 m4.8 m5.4 m6 m7.7 m7.3 m7.9 m7.8 m5.1 m1.4 m4.2 m8.5 m

General and administrative expense

2.2 m2.3 m2.4 m2.5 m3.6 m2.4 m2.5 m2.8 m2.4 m2.1 m1.6 m5.1 m1.8 m

Operating expense total

5.3 m6.8 m7.2 m7.9 m9.7 m10.2 m9.8 m10.7 m10.2 m7.2 m5.8 m9.3 m32.1 m

Depreciation and amortization

107 k

EBIT

(5.3 m)(6.8 m)(7.2 m)(7.9 m)(9.7 m)(10.2 m)(9.8 m)(10.7 m)(10.2 m)(7.2 m)(5.7 m)(9.3 m)(32.1 m)

EBIT margin, %

(16002%)(6061%)

Interest expense

1 k101 k519 k512 k948 k178 k516 k104 k

Interest income

17.3 k15.3 k16.9 k17.4 k30 k32 k32 k39 k36 k31 k11 k

Pre tax profit

(12 m)(32.3 m)

Income tax expense

470 k5.5 m

Net Income

(5.3 m)(6.4 m)(7.2 m)(7.9 m)(9.6 m)(10.2 m)(9.9 m)(11.2 m)(10.7 m)(8.2 m)(5.9 m)(11.5 m)(26.8 m)

Mast Therapeutics Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

25.7 m35.8 m23.1 m8.5 m22.1 m

Inventories

1.1 m1.1 m1.3 m903 k

Current Assets

45.5 m58.4 m42.3 m12.2 m97.9 m

PP&E

105.7 k188 k226 k99 k925 k

Goodwill

3 m3 m3 m3 m27.1 m

Total Assets

55.2 m70.5 m54.2 m17.9 m159.6 m

Accounts Payable

963.9 k1.4 m2.6 m626 k2.8 m

Current Liabilities

4.8 m8.4 m23.2 m4.9 m6 m

Long-term debt

297 k

Total Debt

297 k

Total Liabilities

8.2 m40.3 m

Additional Paid-in Capital

254.2 m293.7 m298.7 m320.6 m186.5 m

Retained Earnings

(235.1 m)(275 m)(311.1 m)(68.2 m)

Total Equity

47.8 m58.7 m23.9 m9.8 m119.3 m

Financial Leverage

1.2 x1.2 x2.3 x1.8 x1.3 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

Cash

30.2 m29.8 m26.4 m26 m27.9 m21.2 m32.2 m23.5 m24.5 m20.5 m7.8 m61.1 m22.1 m

Current Assets

49.9 m50.6 m47.6 m44.1 m50.6 m44.8 m51.4 m38.2 m35.8 m28.3 m8.2 m63.7 m87.6 m

PP&E

115.1 k106.5 k186.3 k185.7 k248 k230 k250 k199 k171 k148 k88 k672 k837 k

Goodwill

3 m3 m3 m3 m3 m3 m3 m3 m3 m3 m3 m28.2 m27.2 m

Total Assets

59.6 m62.4 m59.4 m56.2 m62.7 m56.8 m63.4 m50.1 m47.7 m40.1 m13.9 m125.8 m128.9 m

Accounts Payable

794.7 k1.4 m1.2 m1.2 m2.3 m2 m2.9 m2.5 m2.3 m1.5 m502 k1.9 m3.4 m

Current Liabilities

4 m6.2 m5.7 m7.5 m9.2 m10.8 m13.5 m22.7 m25.4 m20.9 m6.6 m8.1 m5.4 m

Long-term debt

297 k

Total Debt

297 k

Total Liabilities

6.6 m9.6 m9.1 m10.9 m12.6 m14.2 m29.9 m29.5 m31.3 m26.9 m9.5 m46 m35.2 m

Additional Paid-in Capital

253.7 m265.5 m270.1 m273 m294.7 m297.3 m298.2 m306.7 m313.1 m318 m321 m134.2 m187.4 m

Retained Earnings

(220 m)(227.8 m)(244.7 m)(254.9 m)(264.8 m)(286.2 m)(296.9 m)(305 m)(316.9 m)(54.9 m)(95.1 m)

Total Equity

53.1 m52.8 m50.2 m45.2 m50.1 m42.5 m33.5 m20.7 m16.4 m13.2 m4.4 m79.8 m93.7 m

Financial Leverage

1.1 x1.2 x1.2 x1.2 x1.3 x1.3 x1.9 x2.4 x2.9 x3 x3.2 x1.6 x1.4 x

Mast Therapeutics Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(21.5 m)(28.7 m)(39.8 m)(36.1 m)(29.8 m)

Depreciation and Amortization

39.5 k85 k146 k99 k363 k

Accounts Payable

159 k

Cash From Operating Activities

(17.8 m)(24.6 m)(32.9 m)(37.3 m)(28.2 m)

Purchases of PP&E

(46.8 k)(147 k)(165 k)(8 k)(495 k)

Cash From Investing Activities

(4.8 m)481 k3.4 m15.2 m(69.1 m)

Long-term Borrowings

(3.6 m)

Cash From Financing Activities

25.7 m34.3 m16.8 m7.6 m106.1 m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(5.3 m)(6.4 m)(7.2 m)(7.9 m)(9.6 m)(10.2 m)(9.9 m)(11.2 m)(10.7 m)(8.2 m)(5.9 m)(26.8 m)

Depreciation and Amortization

10.1 k11.5 k22.5 k25.8 k30 k37 k38 k32 k30 k24 k11 k107 k

Accounts Payable

1.2 m1.2 m2.3 m2 m2.9 m2.5 m2.3 m1.5 m502 k(554 k)

Cash From Operating Activities

(9.7 m)

Purchases of PP&E

(19 k)

Cash From Financing Activities

271 k

Interest Paid

334 k

Mast Therapeutics Ratios

USDY, 2018

EV/EBIT

-12.1 x

EV/CFO

-40.2 x

Financial Leverage

1.4 x
Report incorrect company information